UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
____________________________________________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
___________________________________________________________________
Date
of
Report (Date of earliest event reported): November 6, 2007
Transdel
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
333-135970
|
45-0567010
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
|
4225
Executive Square, Suite 460
La
Jolla, CA
|
92037
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 457-5300
|
(Former
name or former address, if changed since last
report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of
|
|
Certain
Officers; Compensatory Arrangements of Certain
Officers.
|
Effective
November 6, 2007, our Board of Directors appointed Anthony S. Thornley as a
director of our company.
Mr.
Thornley currently serves on the Board of Directors at Callaway Golf
Incorporated, Cavium Networks Inc. and Airvana Inc. From February 2002 to June
2005, he served as President and Chief Operating Officer of QUALCOMM, Inc.,
a
wireless communication technology and integrated circuit company. From July
2001
to February 2002 he served as Chief Financial Officer and Chief Operating
Officer of QUALCOMM, and from March 1994 to February 2002, he was the Chief
Financial Officer of QUALCOMM. Prior to joining QUALCOMM, he was with Nortel
Networks, a telecommunications equipment manufacturer, for sixteen years in
various financial and information systems management positions, including Vice
President Finance and IS, Public Networks, Vice President Finance NT World
Trade
and Corporate Controller Nortel Limited. He has also worked for Coopers and
Lybrand in public accounting. Mr. Thornley received his BS degree in Chemistry
from the University of Manchester, England.
Item
8.01 Other
Events.
On
November 6, 2007, we issued a press release announcing Mr. Thornley’s
appointment to our board of directors. The full text of the press release is
attached hereto as Exhibit
99.1.
Item
9.01 Financial
Statements and Exhibits
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated November 6, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date:
November 13, 2007
|
||
|
|
Transdel
Pharmaceuticals, Inc.
|
|
|
By:
|
/s/
John T. Lomoro
|
|
|
John
T. Lomoro
|
||
|
Chief
Financial Officer
|
||
2
INDEX
TO EXHIBITS
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated November 6, 2007
|
Exhibit
99.1
Transdel
Pharmaceuticals Appoints Mr. Anthony S. Thornley to Its Board of
Directors
LA
JOLLA,
CA -- Nov 6, 2007 -- Transdel Pharmaceuticals, Inc. (OTC BB:TDLP.OB),
a
specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically targeted medications, today
announced that Anthony S. Thornley has been appointed to the Company's Board
of
Directors.
Mr.
Thornley currently serves on the Board of Directors at Callaway Golf
Incorporated, Cavium Networks Inc. and Airvana Inc. From February 2002 to June
2005 he served as President and Chief Operating Officer of QUALCOMM, Inc.,
a
wireless communication technology and integrated circuit company. From July
2001
to February 2002 he served as CFO and COO of QUALCOMM and from March 1994 to
February 2002 he was the CFO of QUALCOMM. Prior to joining QUALCOMM, he was
with
Nortel Networks, a telecommunications equipment manufacturer, for sixteen years
in various financial and information systems management positions, including
Vice President Finance and IS, Public Networks, Vice President Finance NT World
Trade and Corporate Controller Nortel Limited. He has also worked for Coopers
and Lybrand in public accounting. Mr. Thornley received his BS degree in
Chemistry from the University of Manchester, England.
"We
are
delighted to have a person of Mr. Thornley's stature join our board of
directors," stated Dr. Juliet Singh, President and Chief Executive Officer
of
Transdel Pharmaceuticals. "His extensive knowledge and experience as a senior
executive in finance, operational and strategic roles and as a public company
director makes him a valuable addition to our board as we continue to create
value for our shareholders."
About
Transdel Pharmaceuticals, Inc.
Transdel
Pharmaceuticals is a specialty pharmaceutical company focused on the development
and commercialization of non-invasive topically delivered medications. The
Company's lead topical drug, Ketotransdel™, utilizes the Company's innovative
patented proprietary Transdel™ cream formulation to facilitate the passage of
ketoprofen, an NSAID, through the skin barrier to reach targeted underlying
tissue where the drug exerts its prolonged localized anti-inflammatory and
analgesic effect. The Company is also investigating other drug candidates and
treatments for transdermal delivery using the patented Transdel™ platform
technology for products in pain management and other therapeutic areas.
Safe
Harbor Statement
The
Statements which are not historical facts contained in this press release are
forward-looking statements that involve certain risks and uncertainties
including but not limited to risks associated with the uncertainty of future
financial results, additional financing requirements, development of new
products, government approval processes, the impact of competitive products
or
pricing, technological changes, the effect of economic conditions and other
uncertainties detailed in the Company's filings with the Securities and Exchange
Commission.